12 January 2012
Cancer Research UK has started a trial of a new breast and ovarian cancer drug in outpatients.
The charity re-launched the trial to treat inherited breast and ovarian cancer led by the Sir Bobby Robson Cancer Trials Research Centre, Newcastle University and The Newcastle upon Tyne Hospitals NHS Foundation Trust.
Phase two of the clinical trial will see women with advanced-stage ovarian and breast cancer given a drug called Rucaparib, which is part of a "promising" collection of drugs known as PARP inhibitors.
Professor Ruth Plummer, the trial's chief investigator, said: "We're seeing encouraging results in women with breast or ovarian cancer treated with PARP inhibitors."
She added that in this phase of the trial patients will be able to go about their daily lives and take the treatment at home instead of spending lots of time in hospital facilities.
According to the charity, more than 80 per cent of people diagnosed with breast cancer in England and Wales live for at least five years after diagnosis.
Posted by Philip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.